Donati Valentina, Lupi Cristiana, Alì Greta, Corsi Valentina, Viti Andrea, Lucchi Marco, Mussi Alfredo, Fontanini Gabriella
Section of Pathological Anatomy II, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Int J Mol Med. 2009 Oct;24(4):473-9. doi: 10.3892/ijmm_00000255.
The histologic heterogeneity of lung adenocarcinoma is well known. Many histologic subtypes have been described, and recently their prognostic and predictive value has emerged. Laser capture microdissection may aid in the isolation of cancer cells from distinct subtypes of lung adenocarcinoma, thus enabling the description of their specific molecular features. Characterization of epidermal growth factor receptor (EGFR) mutations in histologic subtypes of lung adenocarcinoma has become an important issue. The purpose of this study was to analyze EGFR mutations in exons 18-21 in single histologic subtypes of lung adenocarcinoma after laser capture microdissection. A revision and reclassification of a series of 208 non-small cell lung cancers was conducted, and 62 adenocarcinomas with a total of 119 histologic component subtypes were identified. Laser capture microdissection of each subtype was performed. EGFR mutations in exons 18-21 were detected using polymerase chain reaction single-strand conformation polymorphism and direct DNA sequencing. EGFR mutations were detected only in 3 out of the 62 adenocarcinomas analyzed. Two adenocarcinomas harbored EGFR mutations in exon 19 (the E746-T751 deletion VA insertion and the LREAT deletion) and one adenocarcinoma the EGFR exon 21 L858R missense point mutation. EGFR mutations were observed in all component subtypes. This suggests that, in a patient with lung adenocarcinoma, EGFR mutations are not associated with particular component histologic subtypes and probably occur at an early stage of tumorigenesis. Notably, 2 out of the 3 mutated adenocarcinomas had a bronchioloalveolar component, whereas the third mutated adenocarcinoma had a papillary subtype. Although we detected EGFR mutations only in 3 out of 62 adenocarcinomas and EGFR mutations were present in every subtype of each mutated adenocarcinoma, our research might represent a basis for further studies in characterizing molecular profiles of different component subtypes of lung adenocarcinoma.
肺腺癌的组织学异质性是众所周知的。已经描述了许多组织学亚型,并且最近它们的预后和预测价值也已显现。激光捕获显微切割有助于从肺腺癌的不同亚型中分离癌细胞,从而能够描述其特定的分子特征。肺腺癌组织学亚型中表皮生长因子受体(EGFR)突变的特征化已成为一个重要问题。本研究的目的是分析激光捕获显微切割后肺腺癌单一组织学亚型中外显子18 - 21的EGFR突变。对一系列208例非小细胞肺癌进行了修订和重新分类,确定了62例腺癌,共有119个组织学成分亚型。对每个亚型进行了激光捕获显微切割。使用聚合酶链反应单链构象多态性和直接DNA测序检测外显子18 - 21中的EGFR突变。在分析的62例腺癌中仅在3例中检测到EGFR突变。2例腺癌在外显子19中存在EGFR突变(E746 - T751缺失VA插入和LREAT缺失),1例腺癌存在EGFR外显子21 L858R错义点突变。在所有成分亚型中均观察到EGFR突变。这表明,在肺腺癌患者中,EGFR突变与特定的成分组织学亚型无关,可能发生在肿瘤发生的早期阶段。值得注意的是,3例突变腺癌中有2例具有细支气管肺泡成分,而第三例突变腺癌具有乳头状亚型。虽然我们仅在62例腺癌中的3例中检测到EGFR突变,并且每个突变腺癌的每个亚型中都存在EGFR突变,但我们的研究可能为进一步研究肺腺癌不同成分亚型的分子特征奠定基础。